Abstract: Non-functioning pituitary adenomas (NFPA) can be classified as either null cell adenomas or gonadotropin adenomas. NFPAs show few clinical signs and symptoms reflecting hormone production and do not manifest clinically as easily recognizable pituitary hypersecretory syndromes. MRI scans are the best way to detect NFPAs, but unfortunately most of the patients who undergo MRI generally have neuroophthalmological or neurological symptoms. It is therefore necessary to confirm the diagnosis of NFPAs using other methods such as gene expression profiling. However, the expression profiles of NFPA transcripts have been unclear to date. To overcome these diagnostic obstacles and to identify NFPA molecular markers, we used a combined approach involving microdissection, immunostaining and cDNA microarray analysis. Samples were collected from patients clinically diagnosed with NFPA by transsphenoidal resection. The control pituitary gland used in this study was freshly dissected from a patient with a brain tumor. The amount of RNA extracted did not correlate with the immunostaining results, but microarray analysis revealed overexpression of candidate molecules in NFPAs. In particular, SLITRK4 was found to have a specific expression pattern in sub-classified NFPA, and was overexpressed specifically in null cell adenomas. SLITRK4 expression was inversely correlated with the MIB-1 index. Our results suggested that SLITRK4 was expressed while the cells of the pituitary gland were undergoing tumorigenic transformation.
Methods

Samples
The samples used in this study were collected from patients who had been clinically diagnosed with a non-functioning pituitary adenoma (NFPA) by transsphenoidal resection. The clinical features of NFPAs include a normal serum pituitary hormone level or hypopituitarism in the case of pituitary apoplexy, and the absence of pituitary hormone overexpression. The normal pituitary gland used in this study was freshly dissected from an 82-yearold woman with a brain tumor (glioblastoma) without permeation to the pituitary gland. All resected tissues were embedded in OCT compound (Sakura, Torrance, CA, USA) and were snap frozen with isopentane cooled in liquid nitrogen. Frozen sections (10 jtm) were prepared for laser capture microdissection. Three NFPA samples from patients admitted to the Showa University Hospital in [2005] [2006] (Table 2) were microdissected and used for subsequent microarray analysis. These included two gonadotropin adenomas and one null cell adenoma. Fourteen NFPA samples from patients admitted to the Showa University Hospital in 2004-2006 were microdissected and used for the reverse transcription polymerase chain reaction (RT PCR) study. These included seven gonadotropin adenomas and seven null cell adenomas.
This study was approved by the Showa University Ethical Review Board. This method involved annealing T7 oligomers to the 5'-terminal of the RNA for cDNA synthesis, and reverse transcription reactions using aminoallyl-UTP to synthesize aminoallyl-aRNA.
Microarray analysis Aminoallyl-aRNA was labeled with Cy3 and microarray analysis was performed using the Whole Human Genome Oligo DNA Microarray Kit (Agilent Technologies)4). Data were analyzed using Genespring GX Software (Agilent Technologies). Real-time RT PCR Total RNA was extracted from cells isolated by LCM. Real-time RT PCR analysis was performed using the QuantiTect SYBR Green RT PCR Kit (Qiagen, Tokyo, Japan) and an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Japan Inc., Tokyo, Japan). All samples were standardized to /3-actin to control for variations in the amount of mRNA. The genes analyzed and primer sets used are listed in Table 4 .
Results
Immunostaining versus real-time RT PCR results
Immunostaining results revealed that seven of the 14 NFPA samples produced hypophyseal hormones. Five samples stained positively for FSH, four stained positively for LG and four samples were positive for TSH. However, the immunostaining results did not correlate with the RT PCR results (Table 3) . 
Discussion
Pituitary adenomas have a heterogeneous organization in that they possess cells involved in hormone production as well as blood vessel cells. In addition, these adenomas are too small to undertake accurate analysis of their gene expression profiles. In order to determine the specific gene expression profile of pituitary adenomas it is necessary to overcome these problems.
We were able to achieve this by utilizing an exhaustive microarray method. However, the amplification efficiency of genes with low levels of RNA expression can vary. To overcome this problem we used the LMD technique, which allowed us to isolate single neoplastic cells, and adopted the aRNA amplification method, which allowed us to amplify very small amounts of RNA efficiently. The RT PCR results did not correlate with the inununostaining results in this study. Our immunostaining results were in accordance with those of Katznelson et al, who reported that NFPAs tended to produce gonadotropins and to be of gonadotroph origin, and that the number of samples positive for FSH and LH expression was high5). In addition, many of the samples in the current study appeared to be TSH positive. It was thought that a TSH production cell was affected by some kind of factors produced by a gonadotropin production cell than from this result though it was not the gonadotropin production cell origin.
SLITRK has a characteristic expression pattern in the cerebral membrane, the diencephalon and the spinal cord motoneuron. SLITRK acts on the neuron directly and is able to adjust neunte development 6). The SLITRK protein is localized in the cell membrane and has two characteristic leucine-rich repeat domains that are recognized by the secreted axonal growth-controlling protein in the extracellular domain. SLITRK also has high sequence homology with the neurotrophin receptor in their intracellular domains. It is possible that SLITRK could be a useful molecular indicator of the characteristics of different brain tumors7). In particular, it has been shown that overexpression of SLITRK4 in chromaffin cell tumors and neuroblastomas decreases neuronal axial fiber dilation.
Our results indicated that SLITRK4 mRNA was expressed when the pituitary gland cells 
